Business · 20/04/1998
FDA Proposes Revisions to Biologics Regulations for Cellular Therapy Products
The Food and Drug Administration (FDA) is proposing to exempt cellular therapy products from the general safety test (GST) and establish an administrative procedure for obtaining exemptions, aiming to simplify the regulatory process for these products.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →